Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
March 27 2024 - 12:45PM
Transgene appoints Lucie Larguier as Chief Financial Officer and
Christelle Schwoerer as Chief Human Resources Officer
Strasbourg, France, March 27, 2024,
5:45 p.m. CET – Transgene (Euronext Paris: TNG), a
biotech company that designs and develops virus-based
immunotherapies for the treatment of cancer, is pleased to announce
the appointment of Lucie Larguier as Chief Financial Officer (CFO),
effective immediately. Formerly VP, Corporate
Communication and Investor Relations at Transgene, in her new role
as CFO, Lucie Larguier will be responsible for all aspects of the
Company’s financial strategy, management and operations to ensure
efficient delivery of Transgene’s innovative immunotherapy
pipeline. Lucie succeeds Arnaud Dubarry who has stepped down to
pursue other opportunities.
Already a member of the executive management
committee, Lucie Larguier brings a comprehensive, cross-functional
view of the Company’s operations and finances as well as a deep
knowledge of Transgene’s investor base. Since 2016, Lucie has
served as Director Corporate Communications and Investor Relations,
reporting directly to the CEO. Lucie contributed significantly to
the smooth execution of four successful securities transactions, as
well as to strengthening the external visibility of Transgene.
Prior to joining Transgene, Lucie spent more than 10 years in
the consultancy environment, advising companies on their corporate
and financial messages, and contributed to the success of numerous
securities transactions. She is a graduate of the Paris Institute
of Political Studies (Sciences Po), with a Master’s degree in
Communication with a minor in finance.
Alongside this new appointment, Transgene has
promoted Christelle Schwoerer to Chief Human Resources Officer,
effective from April 1, 2024, and she also joins the Executive
Committee. Christelle Schwoerer joined Transgene’s Human Resources
department in 2013, and her knowledge of the organization, its
culture and its employees are real assets in her new, expanded
role. Christelle Schwoerer holds a Master 1 in human resources from
the CNAM Grand-Est and a Master 2 in management and human resources
from the Ecole de Management de Strasbourg, which she obtained in
2020 and 2021, respectively.
Alessandro Riva, MD,
Chairman and CEO of Transgene, commented: “Having worked
extensively with Lucie since taking on the role of CEO, I am
convinced that her knowledge and experience make her an excellent
fit as CFO at Transgene. She identifies closely with the culture we
are building, has made significant contributions to the success of
the company to date and is well placed to support our ambitious
plans to accelerate our pipeline of highly promising cancer
immunotherapies.”
Lucie Larguier, Chief Financial Officer,
said: “I am immensely excited to take on the role of CFO
at Transgene. I believe that the company is at a critical juncture,
with ongoing clinical development projects which, if positive,
could deliver significant value to the company and its shareholders
over the next one to two years. I look forward to working closely
with the senior management team to help ensure the success of our
exciting pipeline of cancer immunotherapy assets.”
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (ex-Twitter): @TransgeneSA – LinkedIn: @Transgene
Contacts
Transgene:Lucie
LarguierCFO+33 (0)3 88 27 91 04investorrelations@transgene.fr |
Media: MEDiSTRAVA
Consulting Frazer Hall /Sylvie
Berrebi+44
(0)203 928 6900transgene@medistrava.com |
Disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240327_Transgene_Appoints-LLarguier_CFO_EN
Transgene (EU:TNG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transgene (EU:TNG)
Historical Stock Chart
From Jul 2023 to Jul 2024